Potse Monday, 01/07/19 02:15:30 PM Re: None Post # of 25544 VODG(.208)...expecting FY 2018 results soon..... Extremely high-risk investment because of the filing delinquency. Having said that, I picked up some more shares at .205 last week for possible trading opportunities in the near future. I'm semi-expecting to see the company release a FY 2018 press release soon (perhaps this week). I think there is a reasonably decent chance of seeing increased interest/volume in the stock during 2019 and maybe some nice tradeable moves in the share price. VODG should be entering/continuing a period of growth in the stem cell therapy part of its business. The sales director that the company recently hired looks impressive and should be helpful in the marketing of all products/facets of the business. VODG registered its facility with the FDA for manufacturing/packaging of cosmetic products in mid-December, so it looks like the upcoming cosmetic product is on schedule for introduction in 2019. The CEO recently started updating his personal/business social media presence after about 3 years of silence. Somewhat interesting to note in light of the recent reverse merger between AVOZ and Nurish.me LLC (which has a cognitive/immune supplement line): VODG has a cognitive/immune supplement line called NutraVivo. My hunch is that the company (and the new sales director) will probably try to increase market awareness of this product this year. Although it is not fair to compare VODG to AVOZ (which has a more established market presence) in this particular product area, it is interesting to note that AVOZ is currently trading at a fully-diluted market cap around $300M.